<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04159818</url>
  </required_header>
  <id_info>
    <org_study_id>N19TON</org_study_id>
    <nct_id>NCT04159818</nct_id>
  </id_info>
  <brief_title>Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients</brief_title>
  <acronym>TONIC-2</acronym>
  <official_title>Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients: the TONIC-2 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center non-blinded randomized multi-cohort non-comparative phase II trial
      with a Simon's two-stage design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the first stage, 13 evaluable patients will be accrued per cohort. Evaluable is defined
      as: at least one administration of nivolumab and availability of paired biopsies for
      immunohistochemistry (for induction treatment cohorts pre-induction and pre-nivolumab
      biopsies).

      If there are 1 or no responses observed in these 13 patients, the cohort will be stopped.
      Otherwise, 21 additional patients will be accrued for a total of 34.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients are randomized between experimental cohorts and a control cohort.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Patients are randomized between experimental cohorts and a control cohort.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>assessed monthly until progression or date of death; median 12 months</time_frame>
    <description>Time from randomization to date of first tumor progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>assessed at week 6, 12 and 20 and every 8 weeks thereafter; assessed up to 120 months</time_frame>
    <description>complete response or partial response according to iRECIST and RECIST1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>assessed at week 6, 12 and 20 and every 8 weeks thereafter; assessed up to 120 months</time_frame>
    <description>Beneficial response (complete response, partial response or stable disease) according to RECIST 1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>assessed monthly until date of death; median 12 months</time_frame>
    <description>time from nivolumab initiation to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of all study regimens</measure>
    <time_frame>assessed until 100 days after of treatment end</time_frame>
    <description>adverse events will be graded according to NCI Common Toxicity Criteria v 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival after 6 cycles</measure>
    <time_frame>time from nivolumab initiation to tumor progression or death from any cause; assessed up to 120 months</time_frame>
    <description>the number of patients free of progression after 6 cycles of nivolumab</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>no induction treatment, nivolumab 240 mg flat-dose, every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin induction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin 40mg/m2, weekly for two weeks, after 2 weeks followed by nivolumab 240 mg flat-dose, every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose doxorubicin induction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose doxorubicin 15mg flat dose, weekly for 8 weeks, after 2 weeks followed by nivolumab 240 mg flat-dose, every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>240 mg flat-dose, every 2 weeks. From 20 weeks onwards, nivolumab will be administered every 4 weeks with a flat-dose of 480 mg starting from week 20 onwards</description>
    <arm_group_label>Cisplatin induction</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Low dose doxorubicin induction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>40mg/m2, weekly for two weeks</description>
    <arm_group_label>Cisplatin induction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose doxorubicin</intervention_name>
    <description>15mg flat dose, weekly for 8 weeks</description>
    <arm_group_label>Low dose doxorubicin induction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic or incurable locally advanced triple negative breast cancer (ER &lt; 10%, HER2
             IHC 0,1+ or 2+ with no amplification)

          -  Metastatic lesion accessible for histological biopsy

          -  18 years or older

          -  Maximum of three lines of chemotherapy for metastatic disease and with evidence of
             progression of disease. Treatment with low-dose doxorubicin in the palliative setting
             is not allowed.

          -  WHO performance status of 0 or 1

          -  Measurable or evaluable disease according to RECIST 1.1

          -  Disease Free Interval (defined as time between first diagnosis or locoregional
             recurrence and first metastasis) longer than 1 year

          -  Subjects with brain metastases are eligible if these are not symptomatic and free of
             progression of at least 4 weeks

          -  A maximum dosage of 360 mg/m2 of anthracyclines and no previous anthracycline-related
             cardiac toxicity. In case of radiation in the cardiac area, hypertension, diabetes
             mellitus or hypercholesterolemia, the left ventricular ejection fraction must be 50%
             or higher.

          -  Adequate bone marrow, kidney and liver function

        Exclusion Criteria:

          -  uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris

          -  known history of leptomeningeal disease localization

          -  history of having received other anticancer therapies within 2 weeks of start of the
             study drug

          -  history of immunodeficiency, autoimmune disease, conditions requiring
             immunosuppression (&gt;10 mgl daily prednisone equivalents) or chronic infections.

          -  prior treatment with immune checkpoint inhibitors.

          -  active other cancer

          -  history of uncontrolled serious medical or psychiatric illness

          -  current pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marleen Kok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marleen Kok, MD</last_name>
    <phone>+3120 512</phone>
    <phone_ext>9111</phone_ext>
    <email>m.kok@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leonie Voorwerk, MD</last_name>
    <phone>+3120 512</phone>
    <phone_ext>9111</phone_ext>
    <email>l.voorwerk@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marleen Kok, MD</last_name>
      <phone>+3120512</phone>
      <phone_ext>9111</phone_ext>
      <email>m.kok@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Ingrid AM Mandjes, MSc</last_name>
      <phone>+3120512</phone>
      <phone_ext>9111</phone_ext>
      <email>i.mandjes@nki.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Marleen kok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Triple negative</keyword>
  <keyword>Metastatic disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

